NEW YORK ( The Deal) - Celgene Corp. ( CELG) has made a move to solidify its future in the multiple myeloma space, inking a licensing deal with Germany's MorphoSys AG for its MOR202 drug that could be worth $818 million to MorphoSys. Munich-based MorphoSys gets an up-front license fee of 70.8 million Euros ($92 million) and Celgene will purchase $60 million worth of new shares of the company, the parties said Thursday. Multiple myeloma is a blood cell cancer affecting white blood cells that produce antibodies. It's fairly rare, accounting for only about 1% of cancers, but until recently death occurred between one and four years after diagnosis. With newer drugs, such as those developed by Celgene, survival in many with the disease has been extended several years. Celgene, based in Summit, N.J., is a leader in MM treatments with its U.S.-approved brands Thalomid, Revlimid and Pomalyst. MOR202 would offer an option for revenue replacement in that space as those brands lose exclusivity. The transaction must be cleared by U.S. antitrust authorities under the Hart-Scott-Rodino Act. The price of shares will be determined following that clearance. It will include a premium of at least 15% of the closing price of the shares prior to the parties signing the agreement. Total value of the transaction could hit $818 million for MorphoSys, which may be entitled to additional development, regulatory and sales milestones plus tiered double-digit royalties on net sales outside a co-promotion territory. Celgene secures worldwide rights to MOR202 while sharing the rights with MorphoSys to co-promote the drug candidate in Europe if it is approved there. MorphoSys retains 50-50 profit sharing in its co-promotion territory. MOR202 is a fully human monoclonal antibody targeting CD38 and is in development to treat MM and leukemias. It is now in a Phase 1/2a trial in patients with relapsed/refractory MM. MorphoSys and Celgene will share in the costs of development of the mAb for MM and other indications, with MorphoSys paying one-third of the costs and Celgene two-thirds. Patients continue to need new options for treatment of the disease, said Mark Alles, executive vice president and global head of hematology and oncology at Celgene. "Strategic investments in next-generation medical innovation make it possible for physicians to turn incurable cancers like MM into chronic, more manageable diseases."
At a time when healthcare investors seem especially primed for big, transformative biotech M&A, a deal in which Celgene acquires Biogen would be smart, profitable, opportunistic and certainly attention grabbing.